27.11.2012 Eylea in Europa zugelassen
Eylea: grünes Licht für neues Augenmedikament zur Behandlung der feuchten altersbedingten Makuladegeneration (AMD) in der EU
Weiterlesen: Neues Augenmedikament Eylea gegen AMD erhält Zulassung in Europa
Eylea ™ (VEGF Trap-Eye)
Overview Eylea Treatment for Wet Macular Degeneration (AMD)
December 6, 2012
EYLEA® (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
EYLEA was approved in the United States for the treatment of wet AMD in November 2011 and for macular edema following CRVO in September 2012. EYLEA was also approved in Europe, Japan, Australia, and in several other countries earlier this year for use in wet AMD.
Read more: EYLEA Submitted for EU Marketing Authorization for the Treatment of Macular Edema
Nov. 28, 2012
Bayer's eye drug Eylea approved in Europe
One of Eylea’s key selling points will be its less frequent dosing. Bayer’s drug is given every two months after three initial monthly injections, compared to monthly Lucentis injections.
Read more:Bayer's eye drug Eylea approved in Europe
Nov. 27, 2012
EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Regeneron today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD)
Read more: EYLEA Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Nahrungsergänzungsmittel bei altersbedingter Makuladegeneration
-Anzeige-
Nahrungsergänzungsmittel bei altersbedingter Makuladegeneration
Die Wirksamkeit der Zugabe von Vitaminen und Nahrungsergänzungsmitteln ist derzeit Gegenstand intensiver ärztlicher Forschung. Die Pharmaindustrie bietet inzwischen zahlreiche Präparate an, die aufgrund ihrer speziellen Zusammensetzung bei der Prophylaxe und bei der Behandlung der altersbedingten Makuladegeneration helfen sollen (z.B. Doppelherz system Augen Sehkraft + Schutz).
Sep. 21, 2012
European Medicines Agency - Human medicines - Eylea
On 20 September 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Eylea, 40 mg/ml, solution for injection intended for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Read more: European Medicines Agency - Human medicines - Eylea
25.11.2011
FDA одобрило препарат Eylea для лечения возрастной макулярной дегенерации
Агентство по контролю за продуктами питания и лекарственными средствами США (FDA) одобрило препарат Eylea (афлиберцепт) для лечения влажной формы возрастной макулярной дегенерации
читать далее: FDA одобрило препарат Eylea для лечения возрастной макулярной дегенерации
Nov. 19, 2011
Regeneron Wins FDA Approval for Blindness Drug Eylea
Regeneron Pharmaceuticals Inc. (REGN) won U.S. approval of Eylea, a treatment for a common cause of blindness that will rival Roche Holding AG (ROG)'s Lucentis.
Read more: Regeneron Wins FDA Approval for Blindness Drug Eylea
Nov. 18, 2011
U.S. FDA Approves EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for EYLEA™ Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD).
Nov. 18, 2011
FDA approves Eylea for eye disorder in older people
The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older.
Read more: FDA approves Eylea for eye disorder in older people
Nov. 16, 2011
Media Advisory: For Nov. 18 FDA Decision on Vision Drug, AHAF Experts Available for Comment
For the anticipated FDA announcement on November 18 regarding new treatment for macular degeneration, the American Health Assistance Foundation has experts available for comment, as well as inspiring stories of persons living with the disease.
Read more: Media Advisory: For Nov. 18 FDA Decision on Vision Drug, AHAF Experts Available for Comment
Oct. 24, 2011, AAO
VEGF Trap-Eye Clinical Trial Results Will Be Presented at the American Academy of Ophthalmology 2011 Annual Meeting
The comprehensive year-one findings of the VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) 1 and 2 studies will be reported by Ursula Schmidt-Erfurth, MD, of the Medical University of Vienna, Austria. Results of the Controlled Phase 3 Evaluation of Repeated intravitreal administration of VEGF Trap-Eye in Central retinal vein occlusion: Utility and Safety (COPERNICUS) study will be reported by Julia Haller, MD, of the Wills Eye Institute in Philadelphia.
August 23, 2011 Macular Degeneration Support Canada
Eylea Treatment for Macular Degeneration
A new drug has been developed as a treatment for macular degeneration. The drug named Eylea will compete directly with Lucentis, the current leading treatment for the eye disease.
read more: Eylea Treatment for Macular Degeneration
August 17, 2011 Bloomberg
Regeneron Says FDA Delays Eylea Drug for Blindness
The drug, known as Eylea, would compete with Lucentis from Basel, Switzerland-based Roche Holding AG. (ROG) Eylea is injected every eight weeks, half as often as Lucentis
read more: Regeneron Says FDA Delays Eylea Drug for Blindness
August 16, 2011 Regeneron
Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
Regeneron Pharmaceuticals, Inc. today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency has extended its target date to complete the priority review of the EYLEA Biologics License Application (BLA) for the treatment of neovascular age-related macular degeneration (wet AMD) to November 18, 2011
read more: Regeneron Announces Review of Biologics License Application for EYLEA
29.06.2011 finanznachrichten.de
EYLEA (aflibercept injection) Submitted in Japan for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA'', also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
June 17, 2011 eyedrd
Eylea: A New Drug for Wet Macular Degeneration
A Food and Drug Administration panel voted unanimously Friday to recommend to approve a new Regeneron Pharmaceuticals Inc. eye drug Eylea for the treatment of a condition that can lead to blindness
read more: Eylea - A New Drug for Wet Macular Degeneration
June 17, 2011 RTTNews
FDA Panel Backs Regeneron's Eye Drug Eylea For Wet-AMD
Regeneron Pharmaceuticals Inc. (REGN: News ), said Friday that a panel of the U.S. Food and Drug Administration has unanimously recommended for approval its eye medication Eylea, indicated in the treatment of Wet AMD - a severe eye disorder that results in loss of vision.
read more: FDA Panel Backs Regeneron's Eye Drug Eylea For Wet-AMD
Gefällt Ihnen diese Seite zum Thema "Altersbedingte Makuladegeneration"? Bitte empfehlen Sie diese Informationen zur AMD dann Ihren Freunden und Bekannten:
Neues Mittel gegen Makuladegeneration: EYLEA
